Abstract:Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic targeting capability and binding ability to the vascular endothelial growth factor. The fusion of red blood cell membranes protects the hybrid membrane-coated nanoparticles from phagocytosis by macrophages. In a laser-induced wet age-related macular degeneration mouse model, a significantly enhanced accumulation is observed in CNV regions after intravenous delivery of the hybrid membrane-coated nanoparticles. Moreover, an excellent therapeutic efficacy is achieved in reducing the leakage and area of CNV. Overall, the biomimetic antiangiogenic nanoagents provide an effective approach for noninvasive treatment of CNV.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c00680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c00680</a>.Confirmation of complete hybrid membrane coating onto PLGA nanoparticle cores (Figure S1); long-term stability of [RBC-REC]NPs (Figure S2); self-recognition capability of RECNPs and [RBC-REC]NPs in vitro (Figure S3); targeting affinity to angiogenic endothelial cells in vitro (Figure S4); macrophage uptake of nanoparticles in vitro (Figure S5); biodistribution of nanoparticles in vivo (Figure S6); representative fundus photographs in the day 7 (Figure S7); active-targeting capability of [RBC-REC]NPs in CNV (Figure S8); ability of [RBC-REC]NPs in suppressing endothelial cell migration in vitro (Figure S9); cytotoxic assessment to different ocular cells (Figure S10); biosafety assessment of as-fabricated nanoparticles (Figure S11) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c00680/suppl_file/nn1c00680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Nanoparticle-mediated corneal neovascularization treatments: Toward new generation of drug delivery systems

Nanoparticles in the Ocular Drug Delivery

Nanoceria for Ocular Diseases: Recent Advances and Future Prospects

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

The Phototherapy Toward Corneal Neovascularization Elimination: an Efficient, Selective and Safe Strategy

Biomimetic Nanocomplex Based Corneal Neovascularization Theranostics.

Nano-based Drug Delivery Systems for the Treatment of Non-Infectious Uveitis

In Vivo Assembly Drug Delivery Strategy Based on Ultra-Small Nanoparticles: Toward High Drug Permeation and Accumulation for Cnv Treatment

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

Nanotechnology-based Strategies for Treatment of Ocular Disease

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

An Active Transport Dual Adaptive Nanocarrier Designed to Overcome the Corneal Microenvironment for Neovascularization Therapy.

Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles

Multimodal Photoacoustic Imaging‐Guided Regression of Corneal Neovascularization: A Non‐Invasive and Safe Strategy

Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Corneal neovascularization and treatment